- Asia Pacific
- South Africa
- Hong Kong
- New Zealand
- Czech Republic
- United Kingdom
Recent Pfizer Press Releases
U.S. FDA Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and for the Reduction in the Risk of Recurrent DVT and PE Following Initial Therapy8/21/14 1:31 pm EDT
PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--
- Eliquis demonstrated noninferiority in the primary efficacy endpoint of recurrent symptomatic venous thromboembolism (VTE) or VTE-related death versus enoxaparin/warfarin in the AMPLIFY trial
- Eliquis demonstrated superiority in the primary safety endpoint of major bleeding versus enoxaparin/warfarin in the AMPLIFY trial
Palbociclib Expanded Access Program Now Open To Eligible U.S. Patients With HR+, HER2- Advanced Breast Cancer8/21/14 8:00 am EDTNEW YORK--(BUSINESS WIRE)--Pfizer Inc. today announced that the company has initiated a multi-center, open-label expanded access program (EAP) in the United States for the investigational CDK 4/6 inhibitor, palbociclib. Through the program, palbociclib is being made available for use in combination with letrozole for post-menopausal women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer for whommore...
8/20/14 8:00 am EDT
PRINCETON, N.J. and NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) announced today that they will present 14 abstracts (oral and poster presentations) at the ESC Congress 2014, organized by the European Society of Cardiology, to be held August 30 to September 4 in Barcelona, Spain. The new clinical trial data and GHEOR analyses assessing cost effectiveness and real-world use reinforce the alliance’s commitment to the ongoing analysis ofmore...
- Fourteen abstracts to be presented, including new analyses from the ARISTOTLE®, AMPLIFY® and AMPLIFY-EXT trials evaluating patients with nonvalvular atrial fibrillation (NVAF) and venous thromboembolism (VTE)
- New global health economics and outcomes research (GHEOR) assessing Eliquis cost effectiveness and real-world comparative effectiveness research will also be presented
8/18/14 8:00 am EDTNEW YORK--(BUSINESS WIRE)--Pfizer Inc. today announced it has completed the submission of a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for palbociclib. This NDA requests FDA approval of palbociclib, in combination with letrozole, for the treatment of postmenopausal women with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer who have not received previous systemicmore...
Pfizer Announces FDA Acceptance Of And Priority Review Designation For Biologics License Application For Investigational Meningococcal B Vaccine8/14/14 5:01 pm EDTNEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for bivalent recombinant LP2086 (rLP2086), the company’s vaccine candidate for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B in 10 through 25 year olds. The FDA has also granted Priority Review designation for the BLA, providing an anticipatedmore...
Advisory Committee on Immunization Practices Votes to Recommend Pfizer’s Prevnar 13® Vaccine in Adults Aged 65 Years and Older8/13/14 5:42 pm EDTNEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted to recommend Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein])PCV13) for routine use to help protect adults aged 65 years and older against pneumococcal disease, which includes pneumonia caused by the 13 pneumococcal serotypes included in the vaccine.more...
Pfizer Reports Top-line Results from Postherpetic Neuralgia and Painful Diabetic Peripheral Neuropathy Lyrica® Studies Conducted in China8/12/14 5:01 pm EDTNEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today top-line results from two placebo-controlled studies conducted in China with Lyrica® (pregabalin) in patients with postherpetic neuralgia (pain after shingles or PHN) and painful diabetic peripheral neuropathy (pDPN), respectively. The PHN Phase 4 study, A0081276, met its primary endpoint by demonstrating a statistically significant reduction in pain when compared to placebo. Separately, the pDPN Phase 3more...
European Medicines Agency Accepts Application Seeking New Indication For Prevenar 13®1 For Prevention Of Pneumococcal Pneumonia In Adults8/7/14 8:00 am EDT
Application Includes Data from Pfizer’s Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA)NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that the European Medicines Agency (EMA) has accepted Pfizer’s application seeking to expand the indication for Prevenar 13* (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) in adults to include the prevention of pneumonia caused by the 13 pneumococcal serotypes contained in the vaccine. “Pneumococcal pneumonia continues to be a serious health problem, causingmore...
Rascal Flatts Joins the Thousands of People Who Choose Nexium® 24HR Every Day for Their Frequent Heartburn8/4/14 8:00 am EDT
Join Rascal Flatts Today and Choose Nexium 24HR - Satisfaction GuaranteedNEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that the members of Rascal Flatts, the most-awarded country music band of the past decade, are among the thousands of people who choose Nexium® 24HR every day since becoming available without a prescription for frequent heartburn this past May. Pfizer wants all frequent heartburn sufferers to experience Nexium Level ProtectionTM where they are provided access to the #1 doctor-prescribedmore...
7/30/14 8:00 am EDTNEW YORK--(BUSINESS WIRE)--Pfizer Inc. today announced that it has entered into a definitive agreement to acquire Baxter International Inc.’s portfolio of marketed vaccines for $635 million. As part of the transaction, Pfizer will also acquire a portion of Baxter’s facility in Orth, Austria, where these vaccines are manufactured. Baxter’s portfolio of marketed vaccines consists of NeisVac-C and FSME-IMMUN/TicoVac. NeisVac-C is a vaccine that helps protect againstmore...